You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARP-1 inhibition

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)

Not yet recruiting
  • Prostate Cancer
  • +4 more
  • (no location specified)
Aug 10, 2022

Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body

Recruiting
  • Sarcoma
  • +2 more
  • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
Oct 3, 2023

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +11 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Mar 22, 2022

Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston (drug,

Recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 8, 2022

Breast Cancer Trial in Los Angeles (Pembrolizumab, Olaparib)

Active, not recruiting
  • Breast Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Feb 1, 2023

Cytotoxic Chemotherapy and PARP Inhibition on Genomic Contexture

Recruiting
  • Ovarian Cancer
    • Athens, Greece
      Adamantia Nikolaidi
    Aug 9, 2022

    Ovarian Cancer, Breast Cancer Trial in Dallas (Lynparza)

    Active, not recruiting
    • Ovarian Cancer
    • Breast Cancer
    • Dallas, Texas
      University of Texas Southwestern Medical Center
    Mar 22, 2022

    Prostate Cancer Trial in United States (Niraparib, Leuprolide, Abiraterone Acetate)

    Recruiting
    • Prostate Cancer
    • Ann Arbor, Michigan
    • +3 more
    Oct 18, 2022

    Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma Trial in Oklahoma City (Niraparib)

    Recruiting
    • Recurrent Glioblastoma
    • +3 more
    • Oklahoma City, Oklahoma
      Stephenson Cancer Center
    Jul 20, 2022

    Prostate Cancer Trial in Ann Arbor, Detroit, Charlottesville (Olaparib, AZD6738)

    Active, not recruiting
    • Prostate Cancer
    • Ann Arbor, Michigan
    • +2 more
    Jan 9, 2023

    Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

    Recruiting
    • Recurrent Fallopian Tube Carcinoma
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Jan 12, 2023

    Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Tumors Trial in United States (Olaparib, Tremelimumab)

    Active, not recruiting
    • Ovarian Cancer
    • +2 more
    • Tampa, Florida
    • +4 more
    Jan 12, 2021

    Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

    Not yet recruiting
    • Breast Cancer
    • +7 more
    • (no location specified)
    Sep 26, 2023

    Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

    Active, not recruiting
    • Fallopian Tube Endometrioid Tumor
    • +13 more
    • Orange, California
    • +19 more
    Jan 10, 2023

    Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

    Active, not recruiting
    • Ovarian Neoplasms
    • +2 more
    • KU-0059436 (AZD2281)(PARP inhibitor)
    • Brussels, Belgium
    • +4 more
    Dec 19, 2022

    Lung Cancer Trial in Tianjin (PD-1 inhibitor, PARP inhibitor)

    Recruiting
    • Lung Cancer
    • PD-1 inhibitor
    • PARP inhibitor
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    May 23, 2022

    Pheochromocytoma, Paraganglioma Trial in Philadelphia ([18F]FluorThanatrace ([18F]FTT))

    Not yet recruiting
    • Pheochromocytoma
    • Paraganglioma
    • [18F]FluorThanatrace ([18F]FTT)
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Dec 1, 2022

    Type 1 Diabetes, Type 2 Diabetes Trial in Stockholm (N?-hydroxy-nor-arginine)

    Recruiting
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Nω-hydroxy-nor-arginine
    • Stockholm, Sweden
      Karolinska Institutet
    Apr 10, 2023

    Prostate Cancer Trial in Philadelphia ([18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1)

    Active, not recruiting
    • Prostate Cancer
    • [18F]FluorThanatrace
    • Poly(ADP Ribose) Polymerase 1
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    May 12, 2022

    Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

    Terminated
    • Ovarian Neoplasms
    • +3 more
    • AK112 low dose
    • +2 more
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences and Peking Union Medical Col
    Oct 8, 2022

    Pancreatic Cancer Trial in Philadelphia ([18F]FluorThanatrace ([18F]FTT))

    Recruiting
    • Pancreatic Cancer
    • [18F]FluorThanatrace ([18F]FTT)
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Oct 18, 2021

    Brain Metastases Trial in Houston (Niraparib, Dostarlimab)

    Not yet recruiting
    • Brain Metastases
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 17, 2023

    Multiple Myeloma Trial in Roma, Rome (ATAC-seq and ChIP-seq)

    Recruiting
    • Multiple Myeloma
    • ATAC-seq and ChIP-seq
    • Roma, Italy
    • +1 more
    May 4, 2023

    Type 2 Diabetes in Obese, Obesity, Type2Diabetes Trial in San Diego (SPI-62, Cortisone-d8)

    Completed
    • Type 2 Diabetes Mellitus in Obese
    • +2 more
    • Chula Vista, California
      ProSciento
    Jan 26, 2023